## CITATION REPORT List of articles citing

Economic Evaluation for the UK of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer

DOI: 10.1007/s40273-018-0684-8 Pharmacoeconomics, 2018, 36, 1333-1343.

Source: https://exaly.com/paper-pdf/71404233/citation-report.pdf

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
9	Economic Evaluation for USA of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer. <i>Pharmacoeconomics</i> , <b>2018</b> , 36, 1273-1284	4.4	6
8	Comparing chemotherapy options in metastatic pancreatic cancer. <i>PharmacoEconomics &amp; Outcomes News</i> , <b>2018</b> , 807, 10-10	0.1	
7	Folfirinox gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study. <i>Therapeutic Advances in Gastroenterology</i> , <b>2019</b> , 12, 175	62 <del>8</del> 481	19878660
6	Injectable Hyaluronic Acid Hydrogel for the Co-Delivery of Gemcitabine Nanoparticles and Cisplatin for Malignant Ascites Therapy. <i>Journal of Biomedical Nanotechnology</i> , <b>2020</b> , 16, 1727-1739	4	2
5	Cost-Effectiveness of Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2020</b> , 18, 1528-1536	7-3	6
4	Comparing jurisdiction-specific pharmaco-economic evaluations using medical purchasing power parities. <i>Journal of Medical Economics</i> , <b>2021</b> , 24, 34-41	2.4	2
3	Economic Burden of Pancreatic Cancer in Europe: a Literature Review <i>Journal of Gastrointestinal Cancer</i> , <b>2022</b> , 1	1.6	1
2	Berberine Overcomes Gemcitabine-Associated Chemoresistance through Regulation of Rap1/PI3K-Akt Signaling in Pancreatic Ductal Adenocarcinoma. <b>2022</b> , 15, 1199		1
1	Treatment Costs and Social Burden of Pancreatic Cancer. <b>2023</b> , 15, 1911		O